<DOC>
	<DOCNO>NCT00513240</DOCNO>
	<brief_summary>Brain problem occur neonatal open heart surgery frequency 20-70 % , see neurological examination , brain imaging magnetic resonance imaging ( MRI ) , long term development problem learn disorder hyperactivity syndromes . This study aim determine erythropoetin , natural hormone make body , protect brain damage give high dos neonatal open heart surgery . We use brain MRI , brain wave test ( EEG ) , neurological examination , long term developmental outcome test see erythropoetin good salt water injection ( placebo ) protect brain .</brief_summary>
	<brief_title>Erythropoetin Neuroprotection Neonatal Cardiac Surgery</brief_title>
	<detailed_description>Hypothesis : Erythropoetin ( EPO ) protect neonatal brain perioperative period congenital heart surgery . Using prospective , randomize , placebo-controlled , double-blinded design , specific aim study : 1 . To determine effect perioperative EPO short long term neurological outcome neonates undergoing cardiac surgery optimize cardiopulmonary bypass strategy . 2 . To determine EPO tolerability safety short term administration . 3 . To determine EPO pharmacokinetics population . 4 . To determine relationship neurological monitoring , specifically NIRS , neurological outcome optimize cardiopulmonary bypass technique neonates avoids deep hypothermic circulatory arrest , determine EPO affect relationship . Protocol : Neonates undergo arterial switch , Norwood , aortic arch advancement/other complete 2 ventricle repair , &gt; 35 week gestation ≥2.0 kg eligible . Preop day 1 : NIRS 12-24 hour , neuro exam , Study drug dose # 1 : EPO 500 units/kg saline placebo 12-72 hour surgery . EPO Pharmacokinetic data 25-50 consenting patient . Day surgery : Brain MRI immediately preop . Anesthesia/CPB per standard practice ( fentanyl 100-200 mcg/kg , midazolam , isoflurane , epsilon-aminocaproic acid , 75 mg/kg IV load patient CPB prime , 75 mg/kg/hr infusion OR ) ACP guide TCD , pH stat , hct 30-35 , avoid DHCA . POD # 1 : Study drug dose # 2 : EPO 500 units/kg saline placebo 24 hour dose # 2 . For 72 hour postop , NIRS monitoring . All monitor data collect electronically . POD # 3 : Study drug dose # 3 : EPO 500 units/kg saline placebo 48 hour dose # 3 . 7 day postop : Brain MRI . ( pentobarbital IV ) . Neuro exam discharge . 3-6 month : Brain MRI immediately 2nd surgery , outpatient ( IV pentobarb propofol/midazolam—may use N2O/sevo induction , intubate outpatient ; OR cardiac MRI time , indicate anesthetic technique ) . NIRS x 24h 2nd surgery . 1 , 3 year : Bayley Scales Infant Development III . 5 year : Battery neurodevelopmental test . Early primary outcome variable : MRI severity injury score ( decrease 25 % ) . Late outcome variable Bayley Scales Infant Development score : improvement 18 % age 1 year . Sample size : 60 patient : stratify 3 group give power 0.85 , alpha 0.05 . Expect accrue 2-4 patient per month .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
	<mesh_term>Transposition Great Vessels</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Neonates ( &lt; 30 day ) undergo cardiac surgery cardiopulmonary bypass enrol . Inclusion criterion include patient : single ventricle : hypoplastic leave heart syndrome variant undergo Norwood Stage I Sano palliation ( SV group ) ; patient Dtransposition great vessel without ventricular septal defect ( VSD ) undergo arterial switch operation VSD closure need ( ASO group ) ; patient interrupt hypoplastic aortic arch intracardiac defect ( VSD , ASD , subaortic stenosis ) undergo complete 2 ventricle repair include aortic arch advancement ( AAA group ) , 2 ventricle lesion schedule complex anatomic repair . Gestational age le 35 week birth Weight le 2 kg Known recognizable dysmorphic syndrome Surgery require cardiopulmonary bypass Preoperative cardiac arrest require chest compression great 3 minute Inability enroll patient great 12 hour preoperatively Aortic crossclamping use CPB time anticipate less 60 minute A nadir temperature bypass great 25° C plan . Presence known contraindication EPO administrationsustained systolic blood pressure &gt; 100 , hemoglobin .18 g/dL , know allergy EPO one component Platelet count &gt; 600,000 per dL , INR &lt; 0.8 . Maternal history major vascular thrombosis , multiple fetal loss ( 3 spontaneous abortion ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Days</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>erythropoetin</keyword>
	<keyword>neuroprotection</keyword>
	<keyword>neonate</keyword>
	<keyword>cardiac</keyword>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>brain magnetic resonance imaging</keyword>
	<keyword>electroencephalogram</keyword>
</DOC>